CJC-1295 No Dac | IPAMORELIN

CJC-1295 No Dac | IPAMORELIN

This research blend combines two growth hormone–axis peptides in a single lyophilized vial: CJC-1295 without DAC (Mod GRF 1-29) and ipamorelin. The formulation pairs a modified GHRH(1-29) analog with a selective growth hormone secretagogue receptor (GHS-R) agonist, allowing concurrent investigation of GHRH and ghrelin / GHS pathway activation. CJC-1295 No DAC is a 29-amino-acid modified GRF(1-29) sequence with D-Ala², Gln⁸, Ala¹⁵, and Leu²⁷ substitutions designed to resist DPP-IV cleavage, offering a shorter pulsatile pharmacokinetic profile compared to the DAC-linked variant. CJC-1295 No Dac | IPAMORELIN.

Ipamorelin is a selective pentapeptide GHS-R1a agonist studied for its specificity over cortisol, prolactin, ACTH, and aldosterone pathways. The 10 mg blend (5 mg + 5 mg) is one of the most widely cited GH-axis research stack combinations in the peptide research literature, paired as a tool for studying GHRH + GHS-R receptor synergy in pituitary GH release research. CJC-1295 No Dac | IPAMORELIN.

Benefits (Research Focus)

• Combined GHRH + GHS-R activation — studied for paired pathway stimulation of the somatotropic axis

• Pulsatile GH release — investigated for physiologic-pattern growth hormone release in research models

• IGF-1 axis signaling — explored for downstream hepatic IGF-1 production and somatotropic endpoints

• Receptor-pathway differentiation — examined for paired GHRH receptor and GHS-R1a receptor pharmacology

• Hormone selectivity — researched for ipamorelin’s reported minimal off-target effects on cortisol, prolactin, and ACTH

What Researchers Look At

• Plasma GH and IGF-1 dynamics following paired peptide administration

• Pulsatile vs sustained GH release across paired GHRH and GHS-R stimulation

• Cortisol, prolactin, and ACTH response panels (selectivity markers)

• DPP-IV resistance and peptide pharmacokinetic profiles across components

• Comparative pharmacology versus tesamorelin-based blends and single-component administration

Quick Specs

• Form: Lyophilized white powder

• CJC-1295 (no DAC): 5 mg per vial

• Ipamorelin: 5 mg per vial

• Total Peptide Content: 10 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC (per component)

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound 1: CJC-1295 without DAC (Mod GRF 1-29)

• Synonyms: Mod GRF 1-29; Modified GRF(1-29); CJC-1295 No DAC; tetrasubstituted GRF(1-29)

• Class: Modified GHRH(1-29) analog; 29 amino acids

• Modification: D-Ala², Gln⁸, Ala¹⁵, Leu²⁷ substitutions for DPP-IV resistance and stability

• Formula / M.W.: C₁₅₂H₂₅₂N₄₄O₄₂, ~3367.95 g/mol

• CAS: 863288-34-0

• Compound 2: Ipamorelin

• Synonyms: NNC 26-0161

• Class: Selective ghrelin / GHS-R1a agonist; pentapeptide

• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

• Formula / M.W.: C₃₈H₄₉N₉O₅, ~711.85 g/mol

• CAS: 170851-70-4

 Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment. CJC-1295 No Dac | IPAMORELIN.